TG Therapeutics rises as early-stage data shows benefit in rare muscle weakness disease

TG Therapeutics

09/06/2026 12:51

** Shares of drugmaker TG Therapeutics TGTX.O rise 3% to $42 premarket
** Co says experimental use of its multiple sclerosis drug Briumvi in myasthenia gravis, a rare disease causing muscle weakness and fatigue, showed 82% of patients improved daily activity ability
** Says average symptom score improved by more than four points in 11-patient early-stage study; treatment was generally well tolerated
** TGTX says has started mid-stage trial testing Briumvi as maintenance therapy to sustain symptom control
** Says about 120 patients to be enrolled; responders to existing drug efgartigimod will get Briumvi or placebo
** Adds it aims to expand Briumvi, already approved for multiple sclerosis, into new indication
** As of last close, stock down ~19% YTD

 (Reporting by Sahil Pandey in Bengaluru)
 ((Sahil.Pandey@thomsonreuters.com))